Elan in €45m deal with British biotech firm
Pharmaceutical giant Elan is to receive $55m (€45.07m) from British biotech firm Vernalis for the North American commericialisation rights to migraine treatment Frova.
Vernalis, formed from a merger of RiboTargets and Vernalis Group, changed its name to Vernalis in 2003.